Stress ulcer prophylaxis in the intensive care unit

TY - JOUR

T1 - Stress ulcer prophylaxis in the intensive care unit

AU - Krag, Mette

AU - Perner, Anders

AU - Møller, Morten H

PY - 2016/4/1

Y1 - 2016/4/1

N2 - PURPOSE OF REVIEW: Stress ulcer prophylaxis (SUP) is considered standard of care in the majority of critically ill patients in the ICU. In this review, we will present the current evidence for the use of SUP in ICU patients, including data on the prevalence of gastrointestinal bleeding and the balance between benefits and harms of SUP.RECENT FINDINGS: The prevalence of overt gastrointestinal bleeding in critically ill patients is in the area of 5%. Consistent risk factors for gastrointestinal bleeding have been identified, but indications for SUP vary considerably. SUP is used in three out of four critically ill patients, most frequently in the form of proton pump inhibitors. A recent systematic review of SUP vs. placebo or no prophylaxis in critically ill patients highlights the lack of evidence supporting the use of SUP. Importantly, data suggest potential harm, including increased risk of nosocomial infections and cardiovascular events.SUMMARY: The prevalence of gastrointestinal bleeding in critically ill patients in the ICU is low, the prognostic importance is ambiguous, and SUP is widely used. The balance between benefits and harms of SUP is unknown, and clinical equipoise exists. High-quality randomized controlled trials and systematic reviews assessing benefits and harms of SUP in ICU patients are highly warranted.

AB - PURPOSE OF REVIEW: Stress ulcer prophylaxis (SUP) is considered standard of care in the majority of critically ill patients in the ICU. In this review, we will present the current evidence for the use of SUP in ICU patients, including data on the prevalence of gastrointestinal bleeding and the balance between benefits and harms of SUP.RECENT FINDINGS: The prevalence of overt gastrointestinal bleeding in critically ill patients is in the area of 5%. Consistent risk factors for gastrointestinal bleeding have been identified, but indications for SUP vary considerably. SUP is used in three out of four critically ill patients, most frequently in the form of proton pump inhibitors. A recent systematic review of SUP vs. placebo or no prophylaxis in critically ill patients highlights the lack of evidence supporting the use of SUP. Importantly, data suggest potential harm, including increased risk of nosocomial infections and cardiovascular events.SUMMARY: The prevalence of gastrointestinal bleeding in critically ill patients in the ICU is low, the prognostic importance is ambiguous, and SUP is widely used. The balance between benefits and harms of SUP is unknown, and clinical equipoise exists. High-quality randomized controlled trials and systematic reviews assessing benefits and harms of SUP in ICU patients are highly warranted.

KW - Anti-Ulcer Agents

KW - Critical Care

KW - Critical Illness

KW - Evidence-Based Medicine

KW - Gastrointestinal Hemorrhage

KW - Humans

KW - Intensive Care Units

KW - Peptic Ulcer

KW - Practice Guidelines as Topic

KW - Prognosis

KW - Proton Pump Inhibitors

KW - Risk Assessment

KW - Risk Factors

KW - Journal Article

KW - Review

U2 - 10.1097/MCC.0000000000000290

DO - 10.1097/MCC.0000000000000290

M3 - Review

C2 - 26849250

SN - 1070-5295

VL - 22

SP - 186

EP - 190

JO - Current Opinion in Critical Care

JF - Current Opinion in Critical Care

IS - 2

ER -